Motus GI to Participate in Life Science Intelligence Emerging Medtech Summit 2020

FORT LAUDERDALE, Fla.–(BUSINESS WIRE)–Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today that its chief executive officer, Tim Moran, will present an overview of the Pure-Vu® System and participate in a panel discussion at the Life Science Intelligence Emerging Medtech Summit 2020 which is being held from February 18 – 20, 2020 at the Ritz-Carlton in Dana Point, Calif.

Oral Presentation:



Introduction to the Pure-Vu System


5:20 PM – 5:30 PM PT on Tuesday, February 18, 2020



This oral presentation will provide an overview of how the Pure-Vu System can be used to clean poorly prepped colons during a colonoscopy procedure to improve visualization so gastrointestinal endoscopists can perform a quality exam. The Pure-Vu System is a U.S. FDA cleared medical device that initiated commercial sales in the U.S. in the Fall of 2019.



Industry panel:



“Insights and opinions from big company executives turned entrepreneurs”



1:05 PM –1:45 PM PT on Wednesday, February 19, 2020



The panel comprised of industry executives, including Mr. Moran, will share experiences and insights based on their transition from big companies to entrepreneurship. It will be moderated by industry insider and Alira Health Senior Partner & VP, David Uffer.

“I’ve had the privilege over the last 20+ years to help commercialize and drive growth at some of the world’s largest medical device companies. This experience has given me a unique perspective and key learnings that have helped me shape Motus GI’s strategy, particularly as we launch our Pure-Vu System to U.S. hospitals. I look forward to participating in a robust conversation with my peers on the panel at the Emerging MedTech Summit,” said Mr. Moran. “Our Pure-Vu® System rapidly and safely cleans an inadequately prepped colon during a colonoscopy procedure enabling endoscopists to have a clear view to perform a quality exam. This functionality can provide a useful alternative to going through another round of 24-hour bowel prep for inadequately prepped patients, including those with potentially high-risk issues such as GI bleeds or other comorbidities.”

About Life Science Medtech Summit

The Emerging Medtech Summit is held annually at The Ritz-Carlton Laguna Niguel in Dana Point, Calif. The event brings together the most innovative medtech startups, active investors, and strategic buyers to deal-make and collaborate about the future of medtech industry. In 2020 100 venture funded medtech startups will be present to share their strategic partnering and investment needs and goals with an audience of active investors and strategic buyers.

About Motus GI and the Pure-Vu® System

Motus GI Holdings, Inc. is a medical technology company, with subsidiaries in the U.S. and Israel, providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions. The Company’s flagship product is the Pure-Vu® System, a U.S. FDA cleared medical device indicated to help facilitate the cleaning of a poorly prepared colon during the colonoscopy procedure. The device integrates with standard and slim colonoscopes to enable safe and rapid cleansing during the procedure while preserving established procedural workflow and techniques. Challenges with bowel preparation for inpatient colonoscopy represent a significant area of unmet need that directly affects clinical outcomes and increases the cost of care in a market segment that comprises approximately 1.5 million annual procedures in the U.S. and approximately 4 million annual procedures worldwide. Motus GI believes the Pure-Vu® System may improve outcomes and lower costs for hospitals by reducing the time to successful colonoscopy, minimizing delayed and incomplete procedures, and improving the quality of an exam. In clinical studies to date, the Pure-Vu® System significantly increased the number of patients with an adequate cleansing level, according to the Boston Bowel Preparation Scale Score, a validated assessment instrument.

For more information, visit and connect with the Company on Twitter, LinkedIn and Facebook.

Forward-Looking Statements

This press release contains certain forward-looking statements. Forward-looking statements are based on the Company’s current expectations and assumptions. The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms, including without limitation, risks inherent in the development and commercialization of potential products, uncertainty in the timing and results of clinical trials or regulatory approvals, maintenance of intellectual property rights or other risks discussed in the Company’s Form 10-K filed on March 26, 2019, and its other filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.


Investor Contact:
Bob Yedid

LifeSci Advisors

(646) 597-6989

Media Contact:
Gloria Gasaatura

LifeSci Communications

(646) 970-4688

error: Content is protected !!